Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pyruvate Clear all
Not listed Phase 4 Interventional

17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts

NCT01712295
View directory record Official record
Conditions
Warts
Interventions
17% Salicylate with ethyl pyruvate, Salicylates
Drug
Lead sponsor
Grossman, Michael, D.P.M.
Individual
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 24, 2026, 10:17 PM EDT
Recruiting No phase listed Observational

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

NCT06305728
View directory record Official record
Conditions
Pancreatic Cyst
Interventions
89Zr-DFO-HuMab-5B1 immunoPET, HP MRI, Blood assay
Diagnostic Test · Combination Product
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 24, 2026, 10:17 PM EDT
Terminated Phase 1 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer

NCT02911467
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pyruvate (13C), MRI
Drug · Device
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 24, 2026, 10:17 PM EDT
Terminated Phase 2 Interventional

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

NCT00107666
View directory record Official record
Conditions
Coronary Disease, Heart Valve Diseases
Interventions
CTI-01 (ethyl pyruvate)
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2006 · Synced Oct 24, 2026, 10:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

NCT06176079
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions
Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush
Drug · Procedure
Lead sponsor
Michael Ohliger, MD PhD
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 24, 2026, 10:17 PM EDT
Recruiting No phase listed Observational

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

NCT06600906
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Hyperpolarized 13C-Pyruvate, Computed tomography (CT), Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 24, 2026, 10:17 PM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers

NCT05041166
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Hyperpolarized [13C] Pyruvate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 10:17 PM EDT
Suspended Phase 2 Interventional

Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency

NCT06422351
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
RP-L301
Biological
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
8 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 24, 2026, 10:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 24, 2026, 10:17 PM EDT
Completed No phase listed Observational

Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

NCT04902833
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia
Interventions
Blood Draw
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 24, 2026, 10:17 PM EDT
Active, not recruiting No phase listed Observational

Pyruvate Kinase Deficiency Global Longitudinal Registry

NCT03481738
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Not listed
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Results available

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

NCT03565367
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Interventions
Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
Other · Drug · Procedure
Lead sponsor
Daniel M. Spielman
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 24, 2026, 10:17 PM EDT
Completed Phase 1 Interventional

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

NCT02947373
View directory record Official record
Conditions
Pediatric Brain Tumors
Interventions
Hyperpolarized Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 24, 2026, 10:17 PM EDT
Terminated Phase 2 Interventional Results available

Thiamine vs. Placebo to Increase Oxygen Consumption After Cardiac Arrest

NCT02974257
View directory record Official record
Conditions
Cardiac Arrest, Shock, Lactic Acidosis, Thiamin Deficiency
Interventions
Thiamine, placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 24, 2026, 10:17 PM EDT
Completed No phase listed Observational

Pyruvate Kinase Deficiency Epidemiological Study (PIECE)

NCT03866590
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Not listed
Lead sponsor
CENTOGENE GmbH Rostock
Industry
Eligibility
5 Years to 30 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pembroke Pines, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 24, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes

NCT07186660
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Glycemic Control for Diabetes Mellitus, Insulin, Ketones, Cardiovascular Health
Interventions
CIR-0602K, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 24, 2026, 10:17 PM EDT
Active, not recruiting Phase 3 Interventional

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

NCT02616484
View directory record Official record
Conditions
Pyruvate Dehydrogenase Complex Deficiency
Interventions
Dichloroacetate (DCA), Placebo, Genotype
Drug · Other · Genetic
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
6 Months to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 24, 2026, 10:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gluconeogenesis Rates and Its Precursors in Pediatric Sepsis

NCT01890928
View directory record Official record
Conditions
Sepsis, Hyperglycemia, Critical Illness
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
5 Years to 19 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 24, 2026, 10:17 PM EDT
Completed Early Phase 1 Interventional Results available

A Dose-Finding Study of AG-348 in Sickle Cell Disease

NCT04000165
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
AG-348
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 24, 2026, 10:17 PM EDT
Completed Not applicable Interventional

A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.

NCT00605930
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Pyruvate, creatine, niacinamide, Placebo
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 24, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Rejuvenated RBC and VO2 Max in Healthy Subjects

NCT03089047
View directory record Official record
Conditions
Erythrocyte Transfusion
Interventions
Transfusion of rejuvenated and washed autolgous RBCs, Transfusion of washed autolgous RBCs
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 24, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Thiamine as an Adjunctive Therapy in Cardiac Surgery

NCT02322892
View directory record Official record
Conditions
Coronary Artery Bypass, Cardiac Surgical Procedures
Interventions
Thiamine, Normal saline solution
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 24, 2026, 10:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

NCT05599048
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI), 13C,15N-Urea
Drug · Procedure
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 24, 2026, 10:17 PM EDT
Completed Phase 1 Interventional

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00308243
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sodium Pyruvate in 0.9% Sodium Chloride Solution
Drug
Lead sponsor
Emphycorp
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Oct 24, 2026, 10:17 PM EDT